Moderate-to-severe atopic dermatitis (AD) is inadequately controlled with current treatments for many patients. Abrocitinib is an oral Janus kinase 1 selective inhibitor under investigation for the treatment of AD.
Objective
The aim of the study was to evaluate patient-reported outcomes in a phase 2b study of abrocitinib in adults with moderate-to-severe AD inadequately controlled by topical therapy (NCT02780167).
Methods
Patients (N = 267) were randomly assigned 1:1:1:1:1 to 12-week, once-daily abrocitinib (200, 100, 30, 10 mg) or placebo. Patient-reported outcomes included pruritus numeric rating scale (average), Patient Global Assessment, Patient-Oriented Eczema Measure, Pruritus and Symptoms Assessment for AD, Dermatology Life Quality Index, and Hospital Anxiety and Depression Scale (HADS).
Results
Abrocitinib 200 or 100 mg resulted in significantly greater improvements from baseline versus placebo in peak pruritus numeric rating scale (by days 2 and 3, respectively), Patient-Oriented Eczema Measure, Pruritus and Symptoms Assessment for AD, Dermatology Life Quality Index, and HADS (200 mg only, by week 1 or 2), and proportions of the patients with Patient Global Assessment clear/almost clear with 2-point or greater improvement (by weeks 1 and 4, respectively) that continued through week 12 (except HADS).
Conclusions
Abrocitinib treatment resulted in rapid (2 days to 2 weeks) and persistent improvements in AD symptoms and impacts in moderate-to-severe disease.
Get full access to this article
View all access options for this article.
References
1.
WilliamsH, FlohrC. How epidemiology has challenged 3 prevailing concepts about atopic dermatitis. J Allergy Clin Immunol, 2006; 118(1):209–213.
2.
Chiesa FuxenchZC, BlockJK, BoguniewiczM, et al.Atopic Dermatitis in America study: a cross-sectional study examining the prevalence and disease burden of atopic dermatitis in the US adult population. J Invest Dermatol, 2019; 139(3):583–590.
3.
WollenbergA, OranjeA, DeleuranM, et al.ETFAD/EADV Eczema Task Force 2015 position paper on diagnosis and treatment of atopic dermatitis in adult and paediatric patients. J Eur Acad Dermatol Venereol, 2016; 30(5):729–747.
4.
DruckerAM, WangAR, LiWQ, et al.The burden of atopic dermatitis: summary of a report for the National Eczema Association. J Invest Dermatol, 2017; 137(1):26–30.
5.
SilverbergJI.Public health burden and epidemiology of atopic dermatitis. Dermatol Clin, 2017; 35(3):283–289.
6.
SilverbergJI, GelfandJM, MargolisDJ, et al.Health utility scores of atopic dermatitis in US adults. J Allergy Clin Immunol Pract, 2019; 7(4):1246–1252.e1.
7.
WeiW, AndersonP, GadkariA, et al.Extent and consequences of inadequate disease control among adults with a history of moderate to severe atopic dermatitis. J Dermatol, 2018; 45(2):150–157.
VazquezML, KailaN, StrohbachJW, et al.Identification of N-{cis-3-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]cyclobutyl}propane-1-sulfonamide (PF-04965842): a selective JAK1 clinical candidate for the treatment of autoimmune diseases. J Med Chem, 2018; 61(3):1130–1152.
10.
GooderhamMJ, FormanSB, BissonnetteR, et al.Efficacy and safety of oral Janus kinase 1 inhibitor abrocitinib for patients with atopic dermatitis: a phase 2 randomized clinical trial. JAMA Dermatol, 2019; 155(12):1371–1379.
11.
Copley-MerrimanC, ZeltS, ClarkM, et al.Impact of measuring patient-reported outcomes in dermatology drug development. Patient, 2017; 10(2):203–213.
12.
US Department of Health and Human Services. Guidance for industry—patient-reported outcome measures: use in medical product development to support labeling claims. 2009. Available at: https://www.fda.gov/media/77832/download. Accessed February1, 2021.
13.
BrédartA, MarrelA, Abetz-WebbL, et al.Interviewing to develop patient-reported outcome (PRO) measures for clinical research: eliciting patients' experience. Health Qual Life Outcomes, 2014; 12:15.
14.
ChalmersJR, SchmittJ, ApfelbacherC, et al.Report from the third international consensus meeting to harmonise core outcome measures for atopic eczema/dermatitis clinical trials (HOME). Br J Dermatol. 2014; 171(6):1318–1325.
15.
LebwohlMG, SimpsonEL, BushmakinAG, et al. Validation of the pruritus and symptoms assessment for atopic dermatitis in adults with moderate to severe atopic dermatitis. Paper presented at The 10th Georg Rajka International Symposium on Atopic Dermatitis; April 11–13, 2018; Utrecht, the Netherlands. Abstract P071.
16.
PhanNQ, BlomeC, FritzF, et al.Assessment of pruritus intensity: prospective study on validity and reliability of the visual analogue scale, numerical rating scale and verbal rating scale in 471 patients with chronic pruritus. Acta Derm Venereol, 2012; 92(5):502–507.
17.
CharmanCR, VennAJ, WilliamsHC. The patient-oriented eczema measure: development and initial validation of a new tool for measuring atopic eczema severity from the patients' perspective. Arch Dermatol, 2004; 140(12):1513–1519.
18.
FinlayAY, KhanGK. Dermatology Life Quality Index (DLQI)—a simple practical measure for routine clinical use. Clin Exp Dermatol, 1994; 19(3):210–216.
19.
ZigmondAS, SnaithRP. The Hospital Anxiety and Depression Scale. Acta Psychiatr Scand, 1983; 67(6):361–370.
20.
SchramME, SpulsPI, LeeflangMMG, et al.EASI, (objective) SCORAD and POEM for atopic eczema: responsiveness and minimal clinically important difference. Allergy, 2012; 67(1):99–106.
21.
BasraMK, SalekMS, CamilleriL, et al.Determining the minimal clinically important difference and responsiveness of the Dermatology Life Quality Index (DLQI): further data. Dermatology, 2015; 230(1):27–33.
22.
YosipovitchG, ReaneyM, MasteyV, et al.Peak pruritus numerical rating scale: psychometric validation and responder definition for assessing itch in moderate-to-severe atopic dermatitis. Br J Dermatol, 2019; 181(4):761–769.
23.
SimpsonEL, GadkariA, WormM, et al.Dupilumab therapy provides clinically meaningful improvement in patient-reported outcomes (PROs): a phase IIb, randomized, placebo-controlled, clinical trial in adult patients with moderate to severe atopic dermatitis (AD). J Am Acad Dermatol, 2016; 75(3):506–515.
24.
DawnA, PapoiuAD, ChanYH, et al.Itch characteristics in atopic dermatitis: results of a web-based questionnaire. Br J Dermatol, 2009; 160(3):642–644.
25.
MollanazarNK, SmithPK, YosipovitchG.Mediators of chronic pruritus in atopic dermatitis: getting the itch out?. Clin Rev Allergy Immunol, 2016; 51(3):263–292.
26.
SilverbergJI, GelfandJM, MargolisDJ, et al.Patient burden and quality of life in atopic dermatitis in US adults: a population-based cross-sectional study. Ann Allergy Asthma Immunol, 2018; 121(3):340–347.
27.
CevikbasF, WangX, AkiyamaT, et al.A sensory neuron-expressed IL-31 receptor mediates T helper cell–dependent itch: involvement of TRPV1 and TRPA1. J Allergy Clin Immunol, 2014; 133(2):448–460.
28.
WahlgrenCF, Tengvall LinderM, HägermarkO, et al.Itch and inflammation induced by intradermally injected interleukin-2 in atopic dermatitis patients and healthy subjects. Arch Dermatol Res, 1995; 287(6):572–580.
29.
ChanLS, RobinsonN, XuL. Expression of interleukin-4 in the epidermis of transgenic mice results in a pruritic inflammatory skin disease: an experimental animal model to study atopic dermatitis. J Invest Dermatol, 2001; 117(4):977–983.
30.
ZhengT, OhMH, OhSY, et al.Transgenic expression of interleukin-13 in the skin induces a pruritic dermatitis and skin remodeling. J Invest Dermatol, 2009; 129(3):742–751.
31.
Chrostowska-PlakD, ReichA, SzepietowskiJC. Relationship between itch and psychological status of patients with atopic dermatitis. J Eur Acad Dermatol Venereol, 2013; 27(2):e239–e242.
32.
BenderBG, LeungSB, LeungDY. Actigraphy assessment of sleep disturbance in patients with atopic dermatitis: an objective life quality measure. J Allergy Clin Immunol, 2003; 111(3):598–602.
